

1 **Title**

2 Evaluation of the protective efficacy of Olyset®Plus ceiling nets for reduction of malaria incidence in
3 children in Homa Bay County, Kenya: a cluster-randomized controlled study protocol

4
5 **Authors**

6 Yura K Ko^{1,2}, Wataru Kagaya³, Protus Omondi⁴, Kelvin B. Musyoka⁴, Takatsugu Okai⁴, Chim W. Chan⁴,
7 James Kongere^{4,5}, Victor Opiyo⁵, Jared Oginga⁵, Samuel M. Mbugua^{6,7,8}, Bernard N. Kanoi^{6,8}, Mariko
8 Kanamori^{9,10}, Daisuke Yoneoka¹¹, Kenya National Bureau of Statistics (KNBS)¹², Kibor Keitany¹³, Elijah
9 Songok¹⁴, Gordon Okomo¹⁵, Noboru Minakawa¹⁶, Jesse Gitaka^{6,8(*)}, Akira Kaneko^{1,4,16(*)}

10

11 ¹Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Sweden

12 ²Department of Virology, Tohoku University Graduate School of Medicine, Japan

13 ³Department of Ecoepidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan

14 ⁴Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Japan

15 ⁵Center for Research in Tropical Medicine and Community Development, Kenya

16 ⁶Center for Research in Infectious Diseases, Directorate of Research and Innovation, Mount Kenya University, Kenya

17 ⁷School of pharmacy and health sciences, United States International University Africa, Kenya

18 ⁸Center for Malaria Elimination, Mount Kenya University, Kenya

19 ⁹Department of Public Health Sciences, Stockholm University, Sweden

20 ¹⁰Institute for the Future of Human Society, Kyoto University, Japan

21 ¹¹Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Japan

22 ¹²Kenya National Bureau of Statistics, Kenya

23 ¹³National Malaria Control Programme, Ministry of Health, Kenya

24 ¹⁴Kenya Medical Research Institute, Kenya

25 ¹⁵Department of Health, Homa Bay County, Kenya

26 ¹⁶Department of Vector Ecology and Environment, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan

27

28 **Correspondence to:** Wataru Kagaya

29 *Senior joint authors

30

31 **Abstract**

32 **Introduction:** Malaria is still a major health problem in sub-Saharan Africa, where 98% of global malaria
33 mortality occurs. In addition, the spread of *Plasmodium falciparum* with partial artemisinin resistance in East
34 Africa and beyond is a great concern. The establishment of more effective vector control, in addition to the
35 current long-lasting insecticide-treated net (LLIN) distribution program, is an urgent task in these areas. One
36 novel vector control candidate is the Olyset®Plus ceiling nets which can overcome the problems of
37 variations in net use behaviors and metabolic resistance to insecticide in vectors. Our preliminary study
38 suggests the protective efficacy and high acceptability of this tool. With this proposed second trial, we aim to
39 evaluate the impact of this tool in a different eco-epidemiological setting in the lake endemic region of
40 Kenya.

41 **Methods:** A cluster randomized controlled trial is designed to evaluate the impact of Olyset®Plus ceiling
42 nets in Ndhiwa Sub-County, Homa Bay County, Kenya. A total of 44 clusters will be randomly assigned in a
43 1:1 ratio to the intervention group (Olyset®Plus ceiling nets) and the control group. The assignment will be
44 accomplished through covariate-constrained randomization of clusters. For the primary outcome of clinical
45 malaria incidence, 38 children from each cluster will be enrolled in a cohort and followed for 18 months. We
46 will also evaluate the effects of the intervention on entomological indicators as well as its acceptance by
47 communities and cost-effectiveness.

48 **Ethics and dissemination:** Ethics approval was provided by the Mount Kenya University Institutional
49 Scientific Ethics Review Committee. Study results will be shared with study participants and communities,
50 the Homa Bay County Government and the Kenya National Malaria Control Programme. Results will also
51 be disseminated through publications, conferences and workshops to help the development of novel malaria
52 control strategies in other malaria-endemic countries.

53 **Trial registration:** UMIN000053873

54

55 **Keywords**

56 Malaria, *Anopheles* mosquito, vector control, Pyrethroid resistance, Ceiling net, Kenya, Cluster-randomized
57 controlled trial

58

59 **Administrative information**

60

Title {1}	Evaluation of the protective efficacy of Olyset®Plus ceiling net on reducing malaria incidence in children in the Great Lake Region, Kenya: study protocol for a cluster-randomized controlled trial
Trial registration {2a and 2b}.	UMIN000053873
Protocol version {3}	Version 5.1
Funding {4}	This work is supported by the Japan International Cooperation Agency (JICA) and Japan Agency for Medical Research and Development (AMED) under the Science and Technology Research Partnership for Sustainable Development Goals (SATREPS) program.
Author details {5a}	Osaka Metropolitan University, Japan Nagasaki University, Japan Tohoku University, Japan National Institute of Infectious Diseases, Japan Mount Kenya University, Kenya National Malaria Control Program, Nairobi, Kenya Kenya National Bureau of Statistics, Nairobi, Kenya Kenya Medical Research Institute, Kenya Homa Bay County, Kenya Karolinska Institutet, Sweden Stockholm University, Sweden

<p>Name and contact information for the trial sponsor {5b}</p>	<p>Department of Virology and Parasitology/Research Center for Infectious Diseases, Graduate School of Medicine, Osaka Metropolitan University (OMU), Japan 1-4-3, Asahimachi, Abeno, Osaka, Osaka, Japan, 545-8585 TEL: ☐+☐81-6-6645-3760 Website: https://ocuparasitology.com/en/</p> <p>Directorate of Research and Innovation, Mount Kenya University (MKU), Kenya General Kago Road, Thika, Kiambu, Kenya Website: https://www.mku.ac.ke</p>
<p>Role of sponsor {5c}</p>	<p>OMU will support project management oversight, trial management, data management, statistical analysis, and research governance. MKU also holds overall authority together with project management and analysis.</p>

61
62
63
64
65
66
67
68
69
70
71
72

73 **Strength and limitations of this study**

- 74 • This study is a cluster-randomized controlled trial (CRCT) to evaluate the efficacy of the
75 Olyset®Plus ceiling net as a novel vector control tool and a complement to current malaria control
76 tools in sub-Saharan Africa.
- 77
- 78 • This marks the second CRCT of the Olyset®Plus ceiling net intervention in the lake endemic region
79 of Kenya, expanding the evidence base to a different eco-epidemiological setting from the previous
80 CRCT, where promising results were observed on Mfangano Island.
- 81
- 82 • Collaboration with local Kenyan institutions such as the Kenya National Bureau of Statistics
83 (KNBS), the National Malaria Control Programme (NMCP), the Kenya Medical Research Institute
84 (KEMRI), and Homa Bay County from the research planning stage is one of the strengths of this
85 trial, allowing for a seamless transition from research implementation in the field to policy
86 development.
- 87
- 88 • One of the anticipated limitations is the possible contamination between intervention and control
89 clusters because we will not set a buffer zone due to the geographical proximity of each cluster. We
90 will try to account for such contamination effects by integrating spatial data into our statistical model.

91
92
93
94
95
96
97
98
99

100 **Introduction**

101 **Background and rationale {6a}**

102 Malaria is still a major health problem, particularly in sub-Saharan Africa, where 98% of global malaria
103 mortality occurs [1]. Although the morbidity and mortality of malaria declined from the 2000s to 2015
104 owing to many investments and interventions, such as long-lasting insecticide-treated nets (LLINs), malaria
105 rapid diagnostic tests (RDTs), and artemisinin-based combination therapies (ACTs), progress has stalled
106 since 2015. Moreover, the spread of *Plasmodium falciparum* partially resistant to ACT in Africa is an
107 enormous concern. Currently five African countries, Rwanda [3], Uganda [4], Eritrea [5], Ethiopia [6], and
108 the United Republic of Tanzania [2] have reported delayed clearance of *P. falciparum* after treatment with
109 ACTs. Kenya's proximity to these countries highlights the urgent need to establish effective vector control,
110 in addition to maintaining antimalarial drug efficacy and strengthening resistance surveillance.

111

112 Among several vector control measures, LLIN is the most widely adopted tool to prevent mosquito bites and
113 interrupt malaria transmission. However, suboptimal uses of LLIN are key factors in reducing the impact of
114 LLIN on the malaria burden. In the Lake Victoria basin, alternative uses of LLIN for fishing and protecting
115 crops and chicks are well-known local behaviors [7,8]. In fact, in many areas including our study sites in
116 Homa Bay County, Kenya, malaria prevalence remains high despite widespread distribution of LLINs and
117 their periodic replacements for more than a decade. This suggests that LLIN alone is insufficient to interrupt
118 malaria transmission in this region.

119

120 Recently, we have proposed a novel vector control tool that covers the ceiling and the gap between the
121 ceiling and the walls of residential structures with co-formulated pyrethroid and piperonyl butoxide (PBO)
122 bed net material, called the Olyset®Plus ceiling net. The benefit of installing the Olyset®Plus ceiling net in
123 addition to conventional LLINs is detailed elsewhere [9]. Briefly, the Olyset®Plus ceiling net provides a
124 combination of physical and chemical protection against mosquitoes which seek human bloodmeal in the
125 house. Furthermore, the ceiling net is semi-permanently installed and requires no further action from end
126 users, thus its protective efficacy is consistently extended to all who sleep in the house and less affected by
127 the variation in conventional LLIN use.

128

129 The aim of this study is to evaluate the efficacy, acceptability, and cost-effectiveness of Olyset®Plus ceiling
130 nets on malaria morbidity and transmission in the Lake Victoria basin of Kenya. Preliminary data from our
131 previous study on Mfangano Island in Lake Victoria [9] suggest a substantial reduction in malaria prevalence
132 among school children and high community acceptance of this tool (unpublished data). With this proposed
133 second trial, we aim to evaluate the impact of this tool in a different eco-epidemiological setting with
134 relatively higher malaria transmission, more frequent human and vector movement, and synergistic impact
135 from other interventions such as indoor residual spraying (IRS) and the RTS,S malaria vaccine. Since
136 effective malaria controls need to be tailored to the local context, evidence of the effectiveness of
137 Olyset®Plus ceiling nets from various transmission settings will increase the appeal of this intervention.
138 Furthermore, considering the recent increase in choices of malaria control tools and the necessity of
139 combining various tools to maximize the impact of the malaria control program, it is important to understand
140 the acceptability and cost-effectiveness of each intervention to guide its future deployment.

141

142 To achieve these objectives, our collaboration with local institutions including the Kenya National Bureau of
143 Statistics (KNBS), the National Malaria Control Programme (NMCP), the Kenya Medical Research Institute
144 (KEMRI), and Homa Bay County, started from the research planning stage. This collaboration is crucial to
145 the seamless transition from field trial to expanded implementation and policy development.

146

147 **Objectives {7}**

148 The study has four research domains: epidemiology, entomology, social aspects, and cost-effectiveness.

149

150 For the epidemiology domain, the primary objective is to determine the protective efficacy of Olyset®Plus
151 ceiling net in reducing malaria clinical incidence in children 6 months to 14 years old over 18 months post-
152 intervention. The secondary objectives are (1) to determine the protective efficacy of Olyset®Plus ceiling
153 nets in reducing *Plasmodium* infection prevalence by PCR in all age groups at 6-, 12-, and 18- months post-
154 intervention; (2) to determine the protective efficacy of Olyset®Plus ceiling nets against the time-to-first
155 *Plasmodium* infection; (3) to determine the spillover effects of Olyset®Plus ceiling nets in reducing

156 *Plasmodium* infection prevalence in all age groups at 6-, 12-, and 18-months post-intervention; and (4) to
157 determine the protective efficacy of Olyset®Plus ceiling net in reducing *Plasmodium* infection incidence in
158 children 6 months to 14 years old over 18 months post-intervention.

159

160 For the entomology domain, the primary objective is to evaluate the impact of Olyset®Plus ceiling nets on
161 the mosquito density of the primary malaria vector species. The secondary objectives are (1) to determine the
162 impact of Olyset®Plus ceiling nets on entomological inoculation rate (EIR) and (2) to determine the
163 prevalence of knockdown resistance (*kdr*) mutations in vectors.

164

165 For the social aspects domain, the primary objective is to assess the determinants of social acceptability of
166 the Olyset®Plus ceiling net in both the intervention and control arms. The secondary objectives are (1) to
167 determine the feasibility of installing the Olyset®Plus ceiling and (2) to determine the appropriateness of fit
168 of the Olyset®Plus ceiling net in the context of households in Ndhiwa Sub-County.

169

170 For the cost-effectiveness domain, the primary objective is to determine the incremental cost effectiveness
171 ratios (ICERs) of adding the Olyset®Plus ceiling net to existing malaria control interventions under field
172 trial conditions. The secondary objectives are (1) to establish the relative contribution to costs of the distinct
173 programmatic elements and identify the inputs that contribute the most to overall costs, and (2) to estimate
174 the potential cost of providing Olyset®Plus ceiling net at a larger scale over 3 and 5 years under operational
175 scenarios.

176

177 **Trial design {8}**

178 The study is an open-label, cluster-randomized controlled trial (CRCT) with 44 clusters evenly divided
179 between the intervention and the control arms. Each cluster will include one or two villages and consist of at
180 least 50 households. A baseline survey will be conducted to determine the pre-intervention *Plasmodium*
181 prevalence and *Anopheles* density, and to collect demographic and socioeconomic data for covariate-
182 constrained randomization of clusters. The baseline survey will be conducted one month before cluster
183 randomization. The post-intervention follow-up period will be 18 months. For the evaluation of the primary

184 objective, 38 children aged 6 months to 14 years from each cluster will be recruited and followed for 18
185 months as a cohort. Cross-sectional surveys will be conducted after 6, 12, and 18 months of the intervention
186 targeting 50 individuals of all ages from each cluster to estimate the overall *Plasmodium* prevalence.

187

188 **Methods: Participants, interventions and outcomes**

189 **Study setting {9}**

190 *Location and administrative structure*

191 Ndhiwa (713.5 km²) is one of nine sub-counties in Homa Bay County in Kenya. The sub-county has seven
192 administrative wards: Kanyamwa Kologi, Kanyamwa Kosewa, Kabuoch North, Kwabwai, Kanyadoto,
193 Kanikela, and Kabuoch South/Pala. Based on the number of malaria cases reported in the Kenya Health
194 Information System (KHIS), the accessibility of the site, and population size, we selected Kanyamwa Kologi
195 Ward as the target area (Figure 1). Agriculture is the primary economic activity, with sugarcane as a main
196 commercial crop. County residents also keep animals such as dairy cattle, beef cattle, sheep, goats, and
197 poultry [10]. The ward experiences a long rainy season from March to June and a short rainy season from
198 October to December. As of 2019, the mean annual precipitation is 228.64 mm and the mean annual
199 temperature is 26.7°C. The relative humidity remains elevated year-round, fluctuating between 75% to 85%
200 [11].

201

202 *Demographics*

203 The population of Kanyamwa Kologi Ward is approximately 33,000 according to the 2019 national census
204 [12]. The dominant ethnic group in the region is Luo and the primary languages are DhoLuo, Kiswahili, and
205 English. There are 172 primary and 36 secondary schools in Ndhiwa Sub-County [13]. Within Kanyamwa
206 Kologi Ward, there are 28 primary and 7 secondary schools.

207

208 *Malaria epidemiology and control measures*

209 Based on the KHIS, there were 429.1 and 457.2 confirmed malaria cases per 1,000 population in Ndhiwa
210 Sub-County and Kanyamwa Kologi Ward, respectively, in 2023. The primary malaria vector in the sub-
211 county is *Anopheles funestus*, which prefers feeding on humans. *An. arabiensis* is also an important malaria

212 vector [14]. In Homa Bay County, LLINs have been distributed every three years since the early 2000s, and
213 IRS and the RTS,S malaria vaccine have been piloted in several areas since 2018 and 2019, respectively
214 [15]. Notably PBO-incorporated LLINs (Veeralin@LN, manufactured by VKA Polymers, Tamil Nadu,
215 India) were distributed in late 2023. In Kanyamwa Kologi Ward, there is one level four hospital and seven
216 health centers.

217

218 **Eligibility criteria {10}**

219 As the ceiling nets are installed per structure, we set the inclusion criteria on a structural basis. The inclusion
220 criteria for the installation of the ceiling nets are (1) residential structures with at least one permanent
221 resident aged 18 years or older in the household, (2) informed consent provided by a resident in the
222 household, and (3) house structure amenable to ceiling net installation in terms of size of the structure,
223 presence of eave, ceiling board, and vertical beams, and material of the top part of the wall. The applicability
224 of the ceiling net installation will be assessed by experienced field staff. The exclusion criteria are (1) vacant
225 structure, confirmed by at least two visits by community health promoters (CHPs), (2) dwelling structure to
226 be vacated or destroyed within the study period, (3) not applicable house structure for the ceiling net
227 installation, and (4) non-residential structures (school, shop, kitchen, storage, and toilet). The inclusion
228 criteria for the prospective cohort are (1) children aged 6 months to 12 years old at the time of enrolment, (2)
229 living in the study area at the time of Olyset®Plus ceiling net installation, (3) having no plan to leave or stay
230 outside the study area for an extended period (longer than one month) over the 18-month follow-up period,
231 and (4) informed consent provided by the participants or the parent or legal guardian. The exclusion criterion
232 is having severe chronic illnesses. The inclusion criteria for cross-sectional malaria surveys for all age
233 groups are (1) living in the study area during the study period, and (2) informed consent being provided by
234 the participants or the parent or legal guardian before each survey. The exclusion criteria are (1) having
235 severe chronic illnesses and (2) pregnancy known at the time of the surveys.

236

237 **Who will take informed consent? {26a}**

238 Written informed consent will be obtained by the study team members who fully understand the study
239 protocol. After eligibility is confirmed, the study team members will present to the potential participant a

240 document containing all relevant information about the study in Luo and English. If the participant cannot
241 read, study information will be conveyed verbally in Luo, Kiswahili, and/or English by the study team
242 members. The potential participant will have opportunities to ask any questions. Agreement to participate
243 will be sought only after the participant indicates complete understanding of the study.

244

245 **Additional consent provisions for collection and use of participant data and biological specimens {26b}**

246 The study information document for ceiling net installation contains the study overview. In addition, the
247 documents for cross-sectional and cohort surveys contain details on collecting, storing, and using personal
248 data and biological specimens during the study.

249

250 **Interventions**

251 **Explanation for the choice of comparators {6b}**

252 In Kenya, LLIN is the most widely used malaria preventive measure. The Division of National Malaria
253 Programme coordinates free LLIN distribution, and the county governments deliver LLINs to residents in all
254 endemic counties every three years. In Homa Bay County, the RTS,S malaria vaccine has been implemented
255 since 2019. The primary purpose of this trial is to demonstrate the superiority in malaria prevention of
256 adding Olyset®Plus ceiling nets to the standard malaria control program. Thus, in the control arm, no
257 Olyset®Plus ceiling nets will be installed, but LLIN use and RTS,S immunization will be allowed in the
258 control and intervention arms as the current best practice. There is no plan for new LLIN distribution during
259 the study period.

260

261 **Intervention description {11a}**

262 In the intervention arm, Olyset®Plus ceiling nets will be installed in all dwelling units where residents sleep,
263 free of charge to the households. All participants will be encouraged to continue to use LLINs, distributed by
264 the Homa Bay County government. In each intervention cluster, 1 CHP and 2 community volunteers will be
265 recruited from the intervention cluster and another 1 CHP from the control cluster will join the team to
266 enable future knowledge dissemination. The net installation team will be trained to install ceiling nets by
267 skilled local research assistants who participated in previous trials. The head (or another adult) of the

268 household eligible to a ceiling net will be notified at least 24 hours before the scheduled installation time.
269 The cost of the ceiling nets and their installation will be covered by the research team. Details of the
270 installation procedure are described in the previous study protocol [9]. Briefly, the ceiling net is a rectangular
271 sheet of Olyset®Plus net with loops sewn along the diagonal seams. The loops are roped to the support
272 beams under the roof and the edges of the net are stapled to the wall.

273

274 **Criteria for discontinuing or modifying allocated interventions {11b}**

275 As the ceiling net is semi-permanently installed, the intervention will only be discontinued if the participant
276 specifically requests the removal of the ceiling net by the study team. There will be no crossover from the
277 control arm to the intervention arm during the follow-up period. Those who migrate between the arms or
278 emigrate from the study areas will be dropped from the study follow-up.

279

280 **Strategies to improve adherence to interventions {11c}**

281 Adherence to the intervention cohort in this study is defined as sleeping in houses with Olyset®Plus ceiling
282 nets. Adherence is monitored indirectly by assessing the number of nights each participant spends outside
283 their house during the bi-weekly interview. During each house visit, CHPs will visually inspect the condition
284 of the ceiling nets. Any visible tear and damage to the ceiling net will be reported to the research team, who
285 will assess the size and location of the damage and perform repair or replace the ceiling net if necessary.

286

287 **Relevant concomitant care permitted or prohibited during the trial {11d}**

288 There is no specific concomitant care prohibited during the trial. All participants in both arms will continue
289 to receive and use free LLIN and have access to standard medical care, including malaria testing by RDT,
290 treatment with ACT and RTS,S malaria vaccination.

291

292 **Provisions for post-trial care {30}**

293 All participants will be under the normal healthcare system in the study setting. No perceived health risks for
294 the intended population are expected with the intervention. Our plan of continuous cross-sectional malaria
295 surveillance after the study period allows us to monitor further parasite transmission in the population.

296

297 **Outcomes {12}**

298 Epidemiological domain: The primary outcome will be symptomatic malaria case incidence, defined as
299 axillary temperature of $\geq 37.5^{\circ}\text{C}$ or a history of fever in the preceding 48 hours, and positive mRDT, in
300 children aged 6 months to 14 years enrolled in the cohort, monitored with biweekly visit and passive case
301 detection in the health facilities during an 18-month follow-up. The secondary outcomes will be (1) the
302 prevalence of *Plasmodium* infections by PCR in all age groups at 6, 12, and 18 months post-intervention, (2)
303 time to first infection defined as the number of days between the start of the intervention and the first PCR
304 positive diagnosis in the cohort of children during the 18-month follow-up period, (3) spillover effect
305 measured with the above-mentioned prevalence parameter, and (4) infection incidence by PCR in the
306 prospective cohort of children aged 6 months to 14 years over 18 months.

307

308 Entomological domain: The primary outcome will be the density of the primary malaria vectors, species
309 composition and sporozoite infection rates. Malaria vector density will be determined using CDC light trap,
310 and species composition and sporozoite infection rates will be determined by microscopy and PCR. The
311 secondary outcomes of the entomology domains will be (1) changes in EIR as a measure of malaria
312 transmission and (2) prevalence of *kdr* mutations associated with insecticide resistance in *Anopheles*
313 mosquitoes captured by light trap.

314

315 Social aspect domain: The primary outcome will be the percentage of households consenting to Olyset®Plus
316 ceiling net installation when offered. In addition, we will include observations and discussions about
317 individual attitudes toward the ceiling net. The secondary outcomes of the social aspect domain will be the
318 percentage of the intact ceiling net, description of damaged net, and the impact on the living environment at
319 6, 12, and 18 months post-intervention.

320

321 Cost-effectiveness domain: The primary outcome will be the incremental cost-effectiveness of adding
322 Olyset®Plus ceiling net to existing malaria control interventions under field trial conditions from the societal

323 and provider perspectives. The secondary outcomes of the cost-effectiveness domains will be (1) the costs of
324 the distinct programmatic elements and the inputs that contribute the most to overall costs, and (2) the cost of
325 providing Olyset®Plus ceiling net at a larger scale over three and five years under operational scenarios.

326

327 **Participant timeline {13}**

328 The schedule of trial activities is presented in Figure 2. The detail of each survey is described in Figure 3.

329

330 **Sample size {14}**

331 The sample size was calculated using the method of Hayes and Moulton [16]. All the sample sizes will be
332 recalculated based on the baseline data, which will be collected about one month before the ceiling net
333 installation.

334

335 *Epidemiological survey*

336 The following calculations were based on the historical data collected from the Lake Victoria region in
337 Kenya with a clinical malaria incidence rate of 0.5 per person-year in children under 14 years old by RDT
338 (unpublished data on Mfangano island), 40% parasite prevalence for all age groups by PCR and a between-
339 cluster coefficient of variation (CV) in incidence rate of 0.24 in both groups. In the study site, RTS,S malaria
340 vaccination began in 2019, with a mass distribution of PBO-incorporated LLINs at the end of 2023.

341 Therefore, the intervention effect is expected to be smaller than those in previous studies and is
342 conservatively assumed to be 25%. Assuming 38 individuals per cluster to be followed for up to 18 months
343 with 20 % loss-to-follow up rate, we require 22 clusters per arm to achieve 80% power to detect a significant
344 incidence rate ratio of 0.75 (25% protective efficacy) at a two-sided type 1 error of 5%. With the number of
345 clusters with 50 individuals per cluster, for the secondary outcome of malaria prevalence by PCR for all age
346 groups, we would achieve 5% type 1 error and 80% power to detect 23.5 % relative reduction. We do not
347 specify the sample size for identifying spillover effects because spillovers tend to have smaller effect sizes
348 relative to total or overall effects, so typically larger sample sizes are required to detect them. Although our
349 study may be underpowered to detect spillovers, we will report the results as an exploratory analysis.

350

351 *Entomological survey*

352 Based on the previous study, we assume a mean vector density (number of mosquitoes per CDC light traps)
353 of 3.3, a standard deviation (SD) of 3.3, and CV of 0.192. For 80% power to detect a 50% decrease in mean
354 mosquito densities at 5% type 1 error level, we need to capture mosquitoes from five houses per cluster.

355

356 **Recruitment {15}**

357 Thirty-eight eligible children in each cluster will be randomly recruited into our cohort . Recruitment will be
358 limited to children aged 12 or younger, to avoid children aging out during the 18-month monitoring period.

359 Study team staff will obtain informed consent from the parents or caregivers of the children before enrolling
360 the children in the cohort. For the cross-sectional survey at each time point, we will randomly select from
361 each cluster 50 individuals of all age groups . To guarantee the representativeness for all age groups, the
362 selection will be done with following age category stratifications; 0-4, 5-9, 10-14, 15-19, and 20 and above.

363

364 **Assignment of interventions: allocation**

365 **Sequence generation {16a}**

366 Random numbers will be generated using the sample function in R software.

367

368 **Concealment mechanism {16b}**

369 The individual, household, and villages (clusters) are all given unique IDs at the beginning of the baseline.

370 Any following steps handle only these anonymized IDs.

371

372 **Implementation {16c}**

373 After the baseline survey, covariate-constrained randomization will be used to allocate the 44 clusters across
374 the two study arms. The following factors will be constrained: baseline malaria infection prevalence by RDT
375 in children aged 0.5–14 years, LLIN usage, malaria vaccine coverage, socioeconomic status (SES),
376 population size, the proportion of eligible houses for the ceiling net installation, and vector densities. An
377 independent statistician will perform the randomization. Local study assistants will perform participant

378 enrollment.

379

380 **Assignment of interventions: Blinding**

381 **Who will be blinded {17a}**

382 Due to the visibility of the Olyset®Plus ceiling net, neither the trial participants nor the members of the study
383 team who take part in field activities can be blinded. However, laboratory- and office-based personnel (e.g.,
384 microscopists, laboratory technicians, and data analysts) will be blinded to the identity and intervention
385 status of the trial participants since all biological specimens will be identified by a unique numeric study
386 identifier, and personal information will be removed before analyses.

387

388 **Procedure for unblinding if needed {17b}**

389 This is an open-label trial, and only the data measurers are blinded. Therefore, there is no circumstance that
390 they need to be unblinded.

391

392 **Data collection and management**

393 **Plans for assessment and collection of outcomes {18a}**

394 *Baseline survey*

395 A baseline survey targeting 50 enumeration areas (comprising one or two villages) in the study area will be
396 conducted shortly before the ceiling net intervention to obtain data to assure the balance of the cluster
397 allocation and obtain basic demographic data. The baseline survey includes a questionnaire for all
398 households, mRDT testing of all children aged 6 months to 14 years, and an entomological survey of
399 randomly sampled households. We modified the questionnaire used in the 2020 Kenya Malaria Indicator
400 Survey (KMIS) mainly to quantify the SES of each household and bed net usage. In addition, we add
401 questions to quantify the favorability of ceiling nets before the intervention.

402

403 *Cohort monitoring*

404 Incidence of clinical malaria in the prospective cohort will be estimated by both active and passive case

405 detections. For active case detection, we will conduct home visits every two weeks. Axillary temperature
406 will be measured using a digital thermometer. Participants with fever ($>37.5^{\circ}\text{C}$) or other malaria-related
407 symptoms listed in the Kenya National Malaria Treatment Guideline at the time of home visit or within the
408 previous 48 hours will be tested for malaria by RDT. History of travel, confirmed malaria episode, and visit
409 to local health facilities since the previous visit is recorded. *Plasmodium* infection status will be determined
410 by RDT and PCR from all cohort participants during every other biweekly home visit i.e. every four weeks.
411 For passive case detection, we ask all cohort participants to visit designated health facilities in case they
412 suspect malaria between home visits. The designated facilities are asked to record all malaria tests performed
413 regardless of their results together with the cohort ID. The cost of RDT and anti-malarial treatment will be
414 covered by the research team to encourage cohort participants to use only designated facilities.

415

416 *Cross-sectional malariometric surveys*

417 Malaria prevalence in children and adults will be estimated using cross-sectional malariometric surveys in
418 communities. These surveys will be conducted at 6, 12, and 18 months post-installation. Community surveys
419 will be conducted by house visits.

420 *Plasmodium* infection status will be determined using three methods: RDT, microscopy, and PCR. A finger-
421 prick blood sample will be collected for on-site diagnosis using the Bioline Malaria Ag P.f/Pan RDT (Abbott
422 Diagnostics Korea Inc., Republic of Korea). Survey participants with positive test results will be provided
423 with a treatment course of artemether-lumefantrine with dosing instructions in accordance with guidelines
424 from the Ministry of Health in Kenya after checking their recent treatment history. Blood smears will be
425 prepared on site and transported to the main laboratory in Homa Bay where thin smears are fixed with
426 methanol and all smears are stained with 3% Giemsa solution for 30 minutes, then examined by experienced
427 microscopists. Two blood samples (70 μl each) will be collected with a 75-mm heparinized micro-hematocrit
428 capillary tube (Thermo Fisher Scientific, MA, USA) and spotted on Whatman ET31 Chr filter paper
429 (Whatman International, Maidstone, UK). The blood samples will be allowed to dry at ambient temperature
430 and stored in individual zipped plastic bags at -20°C . The dried blood spots will be used for the determination
431 of malaria status by PCR [17].

432

433 *Entomological surveys*

434 Indoor resting mosquitoes will be collected from five sentinel houses within each cluster using the CDC light
435 trap method. Samples will be preserved in 96% ethanol and placed in a cool box with ice. Specimens will be
436 examined for sex determination by microscopy and species identification by microscopy and PCR. Indoor
437 resting mosquitoes will be collected at baseline, 6, 12 and 18 months post ceiling net installation.

438

439 *Social aspects*

440 We will conduct an exploratory sequential research design using integrated mixed methods (qualitative and
441 quantitative). Qualitative assessment of community perceptions on the Olyset®Plus ceiling nets, community
442 facilitators, and concerns of Olyset®Plus ceiling net use will be implemented, followed by quantitative
443 assessments every 6 months and routine monitoring to evaluate durability and appropriateness of fit of
444 Olyset®Plus ceiling nets using observation checklists. At the end of the study, other qualitative case studies,
445 such as focus group discussions and key informant interviews, will be conducted to document success stories
446 and inform the sustainability and scalability of the intervention.

447

448 *Cost-effectiveness analysis*

449 Incremental financial and economic cost data of Olyset®Plus ceiling net will be collected alongside the
450 intervention. In cases where resources, such as staff, are shared among multiple elements, the allocation of
451 costs will be carried out using an appropriate proxy. Costs related to research activities will be excluded
452 from this allocation. Financial costs will be derived from project expenditure records, while economic costs,
453 which encompass financial expenditures and donated resources, will be identified through project records
454 and social aspects activities. The value of donated resources will be credited based on prevailing market
455 rates. Furthermore, capital costs will be annualized over their useful life for financial costing and annualized
456 at a discount rate of 3% for economic costing.

457

458 **Plans to promote participant retention and complete follow-up {18b}**

459 All surveys planned for the epidemiological and entomological domains will be conducted by house visits.
460 CHPs will make an appointment with eligible participants before each visit to confirm the participants'

461 available date and time. Small remunerations will be provided to survey participants to compensate for their
462 time. CHPs will receive detailed instructions and participatory training for all field procedures and will be
463 actively supervised by the research team throughout the duration of the study. Feedback will be regularly
464 sought from CHPs regarding any issues raised by study participants, and discussions will be held to resolve
465 issues from the field.

466

467 **Data management {19}**

468 All data from the baseline, cohort, and cross-sectional surveys will be captured using the Research Electronic
469 Data Capture (REDCap) software on electronic tablets. Data will be uploaded daily to a highly secure server
470 hosted by Mount Kenya University (MKU). All data from the quantitative surveys will also be stored
471 securely and backed up regularly to prevent data loss. Data access and management of databases will be
472 limited to authorized study investigators and collaborators. After validation of data uploaded to the MKU
473 server, data stored locally on the tablet computers will be permanently deleted to minimize unauthorized
474 access.

475

476 **Confidentiality {27}**

477 To maintain confidentiality, each participant in cross-sectional surveys, the longitudinal cohort, and the
478 quantitative surveys is assigned a unique identifier. The data collected will be labelled using the unique
479 identifier and stored separately from the key linking personal information (name, date of birth, GPS of each
480 household, and phone number). The data will be kept on a secure server that is only accessible to the
481 research staff. Publications will contain only aggregated data, and no personal information will be included.

482

483 **Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular 484 analysis in this trial/future use {33}**

485 Anonymized blood samples from study participants will be stored and analyzed for *Plasmodium* infections
486 by microscopy and PCR in our laboratory in Homa Bay. Microscopic examinations of adult mosquito
487 specimens will be conducted in our field laboratory in Mbita, while PCR analyses will be conducted in our

488 laboratories in Homa Bay and MKU. Laboratory data outputs will be entered in Microsoft Excel and
489 imported into the database. No human genetic analysis is planned for this study. However, remaining
490 biological materials will be stored indefinitely for future studies unless the participants opt out during the
491 informed consent process. Participants are provided with contact information of the research team and can
492 remove themselves from this study or any future studies at any time without penalty or prejudice.

493

494 **Statistical methods**

495 **Statistical methods for primary and secondary outcomes {20a}**

496 We will follow the CONSORT guidelines extended for CRCT for statistical analysis and result reporting.
497 The intention-to-treat (ITT) analysis is the primary analysis approach for both the primary and secondary
498 objectives for the epidemiological and entomological studies. The per-protocol (PP) analysis is included as a
499 supplementary analysis for the primary and secondary objectives for the epidemiological and entomological
500 studies. Detailed methodologies for the epidemiological part are described in the supplementary file of
501 statistical analysis plan.

502

503 *Clinical malaria incidence*

504 We will determine the protective efficacy of Olyset®Plus ceiling nets against malaria case incidence by
505 comparing clinical malaria incidence rates between arms. We will use mixed effects negative binomial
506 regression accounting for within-cluster correlation of outcomes. Possible confounding factors such as age,
507 sex, bed net usage, house structure, malaria vaccination history, and SES will be adjusted as well as
508 covariates used in the covariate-constrained randomization. In addition, because we will not set a buffer
509 zone, the distance to the nearest household in the other arm will be adjusted in the following analysis to
510 reduce the contamination between two arms. The variable was selected from the previous study [18].

511

512 *Prevalence of malaria infection*

513 The secondary outcome, the prevalence of malaria infection by PCR and microscopy measured at 6, 12, and
514 18 months after the ceiling net installation will be analyzed using mixed effects logistic regression adjusting
515 for the above-mentioned confounding factors.

516

517 *Time to first malaria infection*

518 A Cox proportional hazards model and other survival models will be used to compare time to first malaria
519 infection between arms adjusting for the above-mentioned confounding factors. In addition, we will account
520 for the within-cluster correlation of responses.

521

522 *Exploratory analysis for spillover effects*

523 Evidence for positive spillover effects of the ceiling net on malaria infection prevalence of all age group will
524 be assessed by comparing individuals with no intervention conditioning 1) the distance to ceiling net
525 installed household, and 2) the coverage of surrounding households with ceiling net within 400 m. The
526 distance of 400 m was chosen as the spillover effect appears to attenuate at this distance based on previous
527 reports [19].

528

529 *Entomology*

530 Differences in vector density and EIR between arms will be evaluated by random effects negative binomial
531 regression taking into account the intracluster correlation.

532

533 *Social aspects*

534 We will employ the Framework for Reporting Adaptations and Modifications to Evidence-based
535 Implementation Strategies (FRAME-IS) [20] to document the implementation processes of the ceiling nets,
536 and the Evidence integration triangle framework[21] to align the evidence generated to policy and vector
537 control strategies from the health systems aspect. The theoretical framework in qualitative research will be
538 grounded theory[22]. Data from ethnographic, focus group discussions, key informant interview will be
539 summarized using content thematic analysis. Pre- and post-intervention acceptability to install Olyset®Plus
540 ceiling net intervention will be compared to actual consent using logistic regressions.

541

542 *Cost-effectiveness*

543 The economic and financial costs associated with the Olyset®Plus ceiling net intervention will be presented
544 in total and disaggregated forms, highlighting the relative contribution of each program element to the
545 overall program costs. To facilitate comparisons with other malaria vector control interventions, the costs
546 will be converted into cost per household and per person receiving the intervention annually. Various
547 program scenarios, such as different scales and durations, will be presented to estimate operational
548 implementation costs. Compared to the control group, we will utilize the number of malaria cases averted in
549 the Olyset®Plus ceiling net arm to calculate the DALYs averted using standard methods.

550

551 **Interim analyses {21b}**

552 No interim analysis is planned because neither the insecticide permethrin nor the synergist PBO as
553 formulated in Olyset®Plus LLINs are known to pose significant health and safety risks [9,23].

554

555 **Methods for additional analyses (e.g. subgroup analyses) {20b}**

556 We will perform the same analysis for three age subgroups (≤ 59 months old; 5 years old to 14 years old; 15
557 years old or older) to examine if the effects of Olyset®Plus ceiling net differ by age groups. In addition, we
558 will perform other machine learning based approach such as causal forest and super learner to estimate the
559 conditional average treatment effect.

560

561 **Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing 562 data {20c}**

563 In the cohort, non-adherence to the intervention can be identified by bi-weekly interviews. Participants who
564 regularly sleep outside their homes will be removed from the analyses. The extent and patterns of missing
565 data will be assessed once all data collection has been completed. If necessary, we will apply simple hot-
566 deck imputation methods if the missing fraction for the covariate is $<5\%$ or appropriate multiple imputation
567 approaches if the missing fraction for a covariate are $\geq 5\%$. If a non-ignorable portion of the subjects have
568 missing values on a covariate (due to missing at random or missing completely at random), that covariate
569 may be excluded in the model.

570

571 **Plans to give access to the full protocol, participant level-data and statistical code {31c}**

572 This manuscript is the full protocol. The corresponding author will make the de-identified datasets or any
573 future statistical code available upon reasonable request.

574

575 **Oversight and monitoring**

576 **Composition of the coordinating centre and trial steering committee {5d}**

577 The sampling team, composed of CHPs and laboratory technicians, set up a day-to-day communication
578 group and exchanged their experiences. A local management team of study investigators from Kenya and
579 Japan also joined this, leading and advising the activities and monitoring the sample and data integrity. A
580 monthly meeting will be held by the steering committee composed of all key researchers from Kenya and
581 Japan, including the principal investigator (PI) and co-PI, which aim to monitor the progress of the trial.

582

583 **Composition of the data monitoring committee, its role and reporting structure {21a}**

584 Because this intervention is considered to be of a low-risk nature, this study does not have a data monitoring
585 committee. For additional credibility about study quality, the researchers will consult a third statistician, if
586 necessary.

587

588 **Adverse event reporting and harms {22}**

589 All unanticipated problems will be reported to the research team and Homa Bay County Ministry of Health
590 (MOH) through CHPs. Medical officers from Homa Bay County will assess the relatedness of the reported
591 events to the study and report to the research team, including the PI. In the event of a study-related serious
592 adverse event, the study team will convene a meeting immediately with the MOH and Homa Bay County
593 Teaching and Referral Hospital representatives to review the case and take necessary action. Also, the
594 ceiling net is made of the same materials and chemicals as LLIN already on the market, and is therefore not
595 expected to have significant environmental impact.

596

597 **Frequency and plans for auditing trial conduct {23}**

598 A monthly meeting will be held during the follow-up period to ensure that all surveys and investigations are

599 conducted according to the study protocol. The study is required to submit annual reports and renewal to
600 ethical review boards of Osaka Metropolitan University, Japan, and Mount Kenya University, Kenya.

601

602 **Plans for communicating important protocol amendments to relevant parties (e.g. trial participants,**
603 **ethical committees) {25}**

604 Decisions on important trial amendments must be made through a formal procedure and will be approved by
605 institutional review boards (IRB) at Mount Kenya University and Osaka Metropolitan University. The
606 protocol in the clinical trials registry will also be updated accordingly.

607

608 **Dissemination plans {31a}**

609 Study results will be shared with the study participants and communities, the Homa Bay County Government
610 and the Kenya National Malaria Control Programme. Results will also be disseminated through publications,
611 conferences and workshops to help the development of novel malaria control strategies in other malaria-
612 endemic countries. Suggestions from the participants will also help shape the future improvement of the
613 intervention.

614

615 **Discussion**

616 Global malaria progress has flatlined in recent years: targets of reductions in malaria morbidity and mortality
617 and required funding by 2030 are all off track as of 2023[6]. In addition, *P. falciparum* with partial
618 artemisinin resistance, which has been a problem in the Great Mekong Subregion (GMS) for more than a
619 decade [24] [2–6]. Novel interventions that are cost-effective and widely accepted by local communities are
620 urgently needed to contain the spread of artemisinin-resistant *P. falciparum* in sub-Saharan Africa.

621

622 Early results from our cluster randomized controlled trial of Olyset®Plus ceiling nets on Mfangano Island in
623 Lake Victoria, Kenya suggest that ceiling nets can reduce *Plasmodium* prevalence and are positively
624 received by the local communities. Nevertheless, there are regional differences in housing design, vector
625 abundance and composition, and availability of malaria control interventions. As such the feasibility and
626 acceptability of the ceiling net intervention are likely to depend on local eco-epidemiological context [25].

627 Furthermore, one of the secondary objectives in this study is to measure the spillover effects, i.e. how much a
628 household that does not have a ceiling net benefits from living near a house with a ceiling net. This enables a
629 broader understanding of the impact of the ceiling nets at the community level.

630

631 This trial has several limitations. First, although the study is designed as a cluster-randomized controlled
632 trial, contamination between intervention and control clusters cannot be excluded, as buffer zones between
633 intervention and control clusters cannot be created due to geographic proximity of houses and villages in the
634 ward. A recent study, however, has shown that the spillover effect of interventions on malaria can extend to
635 3 km [26], so buffer zones of a few hundred meters, as set out in many studies, may not be sufficient. We
636 will try to eliminate such contamination effects by integrating spatial data into our statistical model. Second,
637 because of the visible nature of the ceiling net, we cannot exclude open-label and observer biases. It is
638 conceivable that participants receiving ceiling nets may reduce their usage of conventional LLIN, as both
639 interventions are made of the same materials and may be perceived to protect against malaria in the same
640 manner. We aim to reduce such bias as much as possible through repeated reminders by CHPs that ceiling
641 nets serve as an addition to and not a replacement of conventional LLINs. We will conduct surveys and in-
642 depth interviews to elicit participants' perceptions of the ceiling net, which can guide future messaging and
643 implementation. To reduce observer bias, laboratory investigators and data analysts will be blinded. Third, in
644 the study area, pyrethroid+PBO-incorporated LLINs were distributed in 2023. It may reduce the effect of our
645 ceiling net intervention because pyrethroid+PBO-incorporated LLINs are more effective than non-PBO-
646 incorporated LLINs by targeting both *Anopheles* vectors with and without metabolic resistance to
647 pyrethroids. Pyrethroid+PBO incorporated LLINs received a conditional endorsement from the World
648 Health Organization (WHO) in 2017, and approximately half of the LLINs distributed in sub-Saharan Africa
649 in 2022 were of this type [2]. Given the abundance of PBO-incorporated LLINs in the region, it is important
650 to assess the effectiveness of the Olyset®Plus ceiling net as an addition to these LLINs to inform policy
651 recommendations. Recently LLINs combining two different classes of insecticides have been shown to be
652 superior to pyrethroid-based LLINs [27]. When these new LLINs become widely available, the effectiveness
653 of pyrethroid-PBO ceiling nets needs to be re-investigated.

654

655 **Trial status**

656 The Baseline survey was started on April 8, 2024. The recruitment of the intervention participants will be in
657 June 2024. The current protocol is version 5.0 as of April 18.

658

659 **Abbreviations**

660 ACT: artemisinin-based combination therapy

661 CHP: community health promoter

662 CRCT: cluster-randomized controlled trial

663 CV: coefficient of variation

664 *kdr*: knockdown resistance

665 KHIS: Kenya Health Information System

666 ITN: insecticide treated nets

667 IRS: indoor residual spraying

668 LLIN: long-lasting insecticidal nets

669 MKU: Mount Kenya University

670 PBO: piperonyl butoxide

671 RDT: rapid diagnosis tests

672

673 **Declarations**

674 **Acknowledgements**

675 We would like to express our sincere gratitude to this study's participants, field, and laboratory staff. In
676 addition, we acknowledge the collaboration and support of health offices in Homa Bay County, Kenya.

677

678 **Authors' contributions {31b}**

679 AK and JG are co-principal investigators. YKK, WK, and AK developed the original concept. All authors
680 discussed and contributed to the study protocol. YKK, WK, PO, BM, TO, CWC, JK, SM, and MK drafted
681 the manuscript. YKK, WK, CWC, MK, GO, and JG contributed to the revisions of the draft of the

682 manuscript. DY participated as a senior statistician. YKK and MK drafted the statistical analysis plan (SAP)
683 and WK, CWC, and DY revised. The authors read and approved the final manuscript and SAP.

684

685 **Funding {4}**

686 YKK and MK were financially supported by the Japan Society for the Promotion of Science. AK and JG
687 received support from JICA/AMED joint research project (SATREPS) (Grant no. 20JM0110020H0002),
688 Hitachi Fund Support for Research Related to Infectious Diseases, and Sumitomo Chemical Corporation.
689 The funding bodies play no role in the study design, data collection, analysis, interpretation, and publication.

690

691 **Availability of data and materials {29}**

692 The study regimes, consent forms, assent forms, and study-related materials are accessible from the
693 corresponding author. The final trial dataset will be available to all investigators. The corresponding author
694 will make the de-identified datasets and source codes for all analysis available upon reasonable request.

695

696 **Patient and public involvement**

697 Although the study design was developed through discussions among the researchers, consultations with the
698 local population were conducted prior to initiating the baseline survey, and their input was incorporated into
699 the study. Community involvement will also be ongoing during the implementation of interventions and
700 research activities.

701

702 **Ethics approval and consent to participate {24}**

703 Ethics approval was received from Mount Kenya University Institutional Scientific Ethics Review
704 Committee (MKU-ISERC) and is under the review from the Ethics Committee in Osaka Metropolitan
705 University.

706 Written informed consents will be sought from study participants before the baseline survey, installation of
707 ceiling nets, each cross-sectional survey, and the start of prospective cohort surveys. Participants have the
708 right to withdraw from the study at any time, and the option to withhold previously collected samples from
709 any future analyses and studies.

710 The samples collected in this study may potentially be used for other research purposes. This is clearly stated
711 in the informed consent form. In such cases, we will obtain the necessary ethical approval and provide
712 participants with the chance to opt-out from this. All experiments will be carried out in adherence to WHO
713 requirements and the Declaration of Helsinki.

714

715 **Consent for publication {32}**

716 We will not present identifying images or other personal or clinical details of participants. The participant
717 information materials and informed consent form are available from the corresponding author on request.

718

719 **Competing interests {28}**

720 This study was partially supported by a research grant from Sumitomo Chemical Corporation.

721

722 **References**

- 723 1. Noor AM, Alonso PL. The message on malaria is clear: progress has stalled. *The Lancet*. 2022. p.
724 1777.
- 725 2. Rosenthal PJ, Björkman A, Dhorda M, Djimde A, Dondorp AM, Gaye O, et al. Cooperation in
726 Countering Artemisinin Resistance in Africa: Learning from COVID-19. *Am J Trop Med Hyg*.
727 2022;106: 1568–1570.
- 728 3. Stokes BH, Ward KE, Fidock DA. Evidence of Artemisinin-Resistant Malaria in Africa. *The New*
729 *England journal of medicine*. 2022. pp. 1385–1386.
- 730 4. Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P, et al. Increasing Prevalence
731 of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea. *N Engl J Med*. 2023;389: 1191–1202.
- 732 5. Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A, et al. *Plasmodium*
733 *falciparum* resistant to artemisinin and diagnostics have emerged in Ethiopia. *Nature Microbiology*.
734 2023;8: 1911–1919.

- 735 6. World Health Organization. World malaria report 2023. 2023.
- 736 7. Larson PS, Minakawa N, Dida GO, Njenga SM, Ionides EL, Wilson ML. Insecticide-treated net use
737 before and after mass distribution in a fishing community along Lake Victoria, Kenya: successes and
738 unavoidable pitfalls. *Malar J.* 2014;13: 466.
- 739 8. Minakawa N, Dida GO, Sonye GO, Futami K, Kaneko S. Unforeseen misuses of bed nets in fishing
740 villages along Lake Victoria. *Malar J.* 2008;7: 165.
- 741 9. Kagaya W, Chan CW, Kongere J, Kanoi BN, Ngara M, Omondi P, et al. Evaluation of the protective
742 efficacy of Olyset®Plus ceiling net on reducing malaria prevalence in children in Lake Victoria Basin,
743 Kenya: study protocol for a cluster-randomized controlled trial. *Trials.* 2023;24: 354.
- 744 10. Homabay County | Ndhiwa Municipality. [cited 13 Feb 2024]. Available:
745 <https://www.homabay.go.ke/department/ndhiwa-municipality>
- 746 11. Ndhiwa, Homa Bay, KE Climate Zone, Monthly Averages, Historical Weather Data. [cited 13 Feb
747 2024]. Available: <https://weatherandclimate.com/kenya/homa-bay/ndhiwa>
- 748 12. Statistics KNB of SNKNB of. 2019 Kenya Population and Housing Census Reports. 28 Feb 2020 [cited
749 13 Feb 2024]. Available: [https://housingfinanceafrica.org/documents/2019-kenya-population-and-](https://housingfinanceafrica.org/documents/2019-kenya-population-and-housing-census-reports/)
750 [housing-census-reports/](https://housingfinanceafrica.org/documents/2019-kenya-population-and-housing-census-reports/)
- 751 13. Ndhiwa Constituency Schools | ShuleZote. [cited 13 Feb 2024]. Available:
752 <https://shulezote.co.ke/place/constituency/migori/ndhiwa/?page=1>
- 753 14. VectorLink-Kenya-2021-End-of-Spray-Report-Submission-Approved-July-23-2021-sxf-CL.pdf.
754 Available: [https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2021/09/VectorLink-Kenya-2021-End-of-](https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2021/09/VectorLink-Kenya-2021-End-of-Spray-Report-Submission-Approved-July-23-2021-sxf-CL.pdf)
755 [Spray-Report-Submission-Approved-July-23-2021-sxf-CL.pdf](https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2021/09/VectorLink-Kenya-2021-End-of-Spray-Report-Submission-Approved-July-23-2021-sxf-CL.pdf)
- 756 15. End-of-Spray-Report-Kenya-2023.pdf. Available:
757 <https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2023/10/End-of-Spray-Report-Kenya-2023.pdf>

- 758 16. Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. *Int J Epidemiol.*
759 1999;28: 319–326.
- 760 17. Isozumi R, Fukui M, Kaneko A, Chan CW, Kawamoto F, Kimura M. Improved detection of malaria
761 cases in island settings of Vanuatu and Kenya by PCR that targets the Plasmodium mitochondrial
762 cytochrome c oxidase III (cox3) gene. *Parasitol Int.* 2015;64: 304–308.
- 763 18. Multerer L, Glass TR, Vanobberghen F, Smith T. Analysis of contamination in cluster randomized
764 trials of malaria interventions. *Trials.* 2021;22: 613.
- 765 19. Hawley WA, Phillips-Howard PA, ter Kuile FO, Terlouw DJ, Vulule JM, Ombok M, et al.
766 Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in
767 western Kenya. *Am J Trop Med Hyg.* 2003;68: 121–127.
- 768 20. Miller CJ, Barnett ML, Baumann AA, Gutner CA, Wiltsey-Stirman S. The FRAME-IS: a framework
769 for documenting modifications to implementation strategies in healthcare. *Implement Sci.* 2021;16: 36.
- 770 21. Glasgow RE, Green LW, Taylor MV, Stange KC. An evidence integration triangle for aligning science
771 with policy and practice. *Am J Prev Med.* 2012;42: 646–654.
- 772 22. Chun Tie Y, Birks M, Francis K. Grounded theory research: A design framework for novice
773 researchers. *SAGE Open Med.* 2019;7: 2050312118822927.
- 774 23. Minakawa N, Kawada H, Kongere JO, Sonye GO, Lutiali PA, Awuor B, et al. Effectiveness of
775 screened ceilings over the current best practice in reducing malaria prevalence in western Kenya: a
776 cluster randomised controlled trial. *Parasitology.* 2022;149: 1–39.
- 777 24. Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, et al. Molecular epidemiology of
778 resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. *Lancet Infect*
779 *Dis.* 2020;20: 1470–1480.

- 780 25. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, et al. Malaria resurgence: a systematic
781 review and assessment of its causes. *Malar J.* 2012;11: 122.
- 782 26. Benjamin-Chung J, Li H, Nguyen A, Heitmann GB, Bennett A, Ntuku H, et al. Targeted malaria
783 elimination interventions reduce *Plasmodium falciparum* infections up to 3 kilometers away. medRxiv.
784 2023. doi:10.1101/2023.09.19.23295806
- 785 27. Mosha JF, Matowo NS, Kulkarni MA, Messenger LA, Lukole E, Mallya E, et al. Effectiveness of long-
786 lasting insecticidal nets with pyriproxyfen–pyrethroid, chlorfenapyr–pyrethroid, or piperonyl butoxide–
787 pyrethroid versus pyrethroid only against malaria in Tanzania: final-year results of a four-arm, single-
788 blind, cluster-randomised trial. *Lancet Infect Dis.* 2024;24: 87–97.




Figure 1: Map of the study area. Inset shows the locations of the level four hospital and seven health centers (HC) in Kanyamwa Kologi Ward.




Figure 2: The schedule of trial activities.




Figure 3: CONSORT flow diagram and the detail of each survey